RHOA and neoplasm: Key exceptions are RHOA G17V, a loss of function mutation leading to dominant negative inhibition of wild type RHOA GTPase activity18,21 and TP53 R196* a truncation which lacks tumour suppressor activity and is observed in a wide range of solid tumours28.